Is Mar­tin Shkre­li blog­ging from prison?

7 years ago
People

'Bio­hack­er' Tray­wick ac­ci­den­tal­ly drowned, of­fi­cial con­firms

7 years ago
People

What's BIO and PhRMA do­ing to ad­dress sex­u­al ha­rass­ment? Sen­a­tor Mur­ray wants to know

7 years ago
Pharma

Sanofi gets se­ri­ous in Chi­na with plans to hire 300 for $76M R&D site in Cheng­du

7 years ago
R&D
China

MiMedx shares swoon as purge claims CEO; Those big cuts in drug prices you heard about? Pfiz­er has oth­er ideas

7 years ago
News Briefing

Af­ter clos­ing the gap on new hires, FDA could face an ex­o­dus of top reg­u­la­tors

7 years ago
R&D
Pharma

RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing ...

7 years ago
Financing
Startups

With $100M in fresh back­ing and a new TCR ini­tia­tive, Athenex launch­es Chi­na JV

7 years ago
Financing

Roche vaults in­to lead in front­line triple neg­a­tive breast can­cer as Tecen­triq/Abrax­ane com­bo aces pro­gres­sion-free ...

7 years ago
R&D

GSK-backed Liq­uidia takes a seat at the IPO ta­ble, look­ing for a $57.5M stake to take on Unit­ed Ther­a­peu­tics

7 years ago
Financing

For­get the biotech mega-round. Try the $200M-plus Chi­na 'ul­tra' on for size

7 years ago
Financing
China

Af­ter biotech im­plo­sions, ex-Mil­len­ni­um chief Deb­o­rah Dun­sire is tak­ing the helm at Lund­beck

7 years ago
People

No­var­tis to spin off Al­con eye care unit, buy back $5B in stock; Ri­val CAR-Ts from No­var­tis and Gilead get thumbs up ...

7 years ago
News Briefing

An­drew Rit­ter gath­ers the reins as his com­pa­ny preps PhI­II; Sol­id Bio co-founder Gi­lad Hay­eem re­tires

7 years ago
Peer Review

Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

7 years ago
Pharma

How does the first half of 2018 mea­sure up against the last 7 years for biotech IPOs?

7 years ago
Financing
Pharma

Three years lat­er the FDA fi­nal­ly lifts its hold on Ap­tose drug, set­ting the stage for a re­turn to PhIb

7 years ago
Pharma

Bat­tered Gem­phire shares soar on new triglyc­eride da­ta, but there’s a lot left to prove

7 years ago
R&D

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

7 years ago
R&D

Ab­b­Vie re­treats as Gala­pa­gos of­fers mixed PhII CF da­ta, leav­ing a ma­jor al­liance in per­il — Ver­tex shares surge

7 years ago
R&D

Bio­gen goes deep in­to biosim­i­lars, slap­ping down $700M for a ma­jor stake in Sam­sung Bioepis

7 years ago
R&D
Pharma

As Alex­ion fields ap­pli­ca­tions for ALXN1210, a ri­val aims for the crown with head-to-head PhI­II; No­vo hands NBE ...

7 years ago
News Briefing

Ama­zon snaps up on­line phar­ma­cy start­up Pill­Pack in lat­est move to dis­rupt health­care

7 years ago
Deals

Tout­ing PhI­II suc­cess for arthri­tis drug Taltz, Eli Lil­ly chas­es ri­val No­var­tis in heat­ed im­munol­o­gy race

7 years ago
R&D
First page Previous page 1028102910301031103210331034 Next page Last page
A service from the Financial Times